{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"GT60","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"The data presented based on the March DCO (17 May 2018) are not the final analyses for OS, TFST, TSST, and TDT. Further analyses of these (numbered as endpoints 2, 6, 7 and 8 in Outcome Measures section) will be performed as planned in the protocol and SAP when the pre-specified number of OS events are achieved."},"pointOfContact":{"email":"ClinicalTrialTransparency@astrazeneca.com","organization":"AstraZeneca","phone":"+1 302 885 1180","title":"Elizabeth Lowe"}}